Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Simone Brokamp"'
Autor:
Simone Brokamp, Annegien Broeks, Christian U. Blank, Petra Herzig, Marlous van den Braber, Daniela S. Thommen, Alfred Zippelius, Marjolein de Bruijn, Joyce Sanders, Ton N. Schumacher, Lisanne M. Roelofsen, Koen J. Hartemink, John B. A. G. Haanen, Kim Monkhorst, Paula Voabil, Sanne H. Hendriks
Publikováno v:
Nature Medicine. 27:1250-1261
Inhibitors of the PD-1–PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological alterations that occur in human cancer tissue after PD-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c45c19b51a9c099f12311a77da46c458
https://doi.org/10.1038/s41591-021-01398-3
https://doi.org/10.1038/s41591-021-01398-3
Autor:
Paulien Kaptein, Celia Jacoberger-Foissac, Petros Dimitriadis, Paula Voabil, Marjolein de Bruijn, Simone Brokamp, Irene Reijers, Judith Versluis, Gahyathiri Nallan, Hannah Triscott, Elizabeth McDonald, Joshua Tay, Georgina V. Long, Christian U. Blank, Daniela S. Thommen, Michele W.L. Teng
Publikováno v:
Science Translational Medicine, 14(642). AMER ASSOC ADVANCEMENT SCIENCE
Neoadjuvant immunotherapy with anti-cytotoxic T lymphocyte–associated protein 4 (CTLA4) + anti–programmed cell death protein 1 (PD1) monoclonal antibodies has demonstrated remarkable pathological responses and relapse-free survival in ~80% of pat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6676795225993de96cda1c9757ccd80f
https://doi.org/10.1126/scitranslmed.abj9779
https://doi.org/10.1126/scitranslmed.abj9779
Autor:
Paula, Voabil, Marjolein, de Bruijn, Lisanne M, Roelofsen, Sanne H, Hendriks, Simone, Brokamp, Marlous, van den Braber, Annegien, Broeks, Joyce, Sanders, Petra, Herzig, Alfred, Zippelius, Christian U, Blank, Koen J, Hartemink, Kim, Monkhorst, John B A G, Haanen, Ton N, Schumacher, Daniela S, Thommen
Publikováno v:
Nature medicine. 27(7)
Inhibitors of the PD-1-PD-L1 axis have been approved as therapy for many human cancers. In spite of the evidence for their widespread clinical activity, little is known about the immunological alterations that occur in human cancer tissue after PD-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::8094aee10c0eedb40999c71de5771837
https://pubmed.ncbi.nlm.nih.gov/34478641
https://pubmed.ncbi.nlm.nih.gov/34478641